These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 32029085)

  • 1. Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Classes of Glucose-Lowering Medications on Renal Outcome in Type 2 Diabetes.
    Takeuchi M; Ogura M; Minoura T; Inagaki N; Kawakami K
    Mayo Clin Proc; 2020 Feb; 95(2):265-273. PubMed ID: 32029085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
    Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Aug; 20(1):167. PubMed ID: 34399757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes.
    Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
    J Am Heart Assoc; 2021 Jun; 10(11):e020237. PubMed ID: 34013739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function.
    Sada K; Hidaka S; Kashima J; Morita M; Sada K; Shibata H
    J Diabetes Investig; 2022 Aug; 13(8):1330-1338. PubMed ID: 35322583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes.
    Miyoshi H; Kameda H; Yamashita K; Nakamura A; Kurihara Y
    J Diabetes Investig; 2019 Nov; 10(6):1510-1517. PubMed ID: 31026373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
    Schechter M; Melzer-Cohen C; Rozenberg A; Yanuv I; Chodick G; Karasik A; Kosiborod M; Mosenzon O
    Cardiovasc Diabetol; 2021 Aug; 20(1):169. PubMed ID: 34407822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association of Background Medications on Initial eGFR Change and Kidney Outcomes in Diabetic Patients Receiving SGLT2 Inhibitor.
    Chan YH; Chao TF; Chen SW; Kao YW; Huang CY; Chu PH
    Clin J Am Soc Nephrol; 2023 Jul; 18(7):858-868. PubMed ID: 36999982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney outcomes with SGLT2is for type 2 diabetes patients: does background treatment with metformin or RASis matter?
    Chong KS; Chang YH; Lin MH; Hsu CN; Wang CC; Wang CY; Huang YL; Lin FJ; Ou HT
    Front Endocrinol (Lausanne); 2024; 15():1329945. PubMed ID: 38994012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
    Heerspink HJL; Karasik A; Thuresson M; Melzer-Cohen C; Chodick G; Khunti K; Wilding JPH; Garcia Rodriguez LA; Cea-Soriano L; Kohsaka S; Nicolucci A; Lucisano G; Lin FJ; Wang CY; Wittbrodt E; Fenici P; Kosiborod M
    Lancet Diabetes Endocrinol; 2020 Jan; 8(1):27-35. PubMed ID: 31862149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes.
    Sohn M; Nam S; Nauck MA; Lim S
    BMC Med; 2024 Jul; 22(1):273. PubMed ID: 38956548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events.
    Xie Y; Bowe B; Gibson AK; McGill JB; Yan Y; Maddukuri G; Al-Aly Z
    Diabetes Care; 2020 Nov; 43(11):2785-2795. PubMed ID: 32912850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter-2 Inhibitors vs Sulfonylureas for Gout Prevention Among Patients With Type 2 Diabetes Receiving Metformin.
    McCormick N; Yokose C; Lu N; Wexler DJ; Aviña-Zubieta JA; De Vera MA; McCoy RG; Choi HK
    JAMA Intern Med; 2024 Jun; 184(6):650-660. PubMed ID: 38619822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
    Scheen AJ
    Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan.
    Kobayashi K; Toyoda M; Hatori N; Furuki T; Sakai H; Sato K; Miyakawa M; Tamura K; Kanamori A
    J Diabetes Investig; 2021 Aug; 12(8):1408-1416. PubMed ID: 33377605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure after treatment with sodium-glucose cotransporter 2 inhibitors influences renal composite outcome: Analysis using propensity score-matched models.
    Kobayashi K; Toyoda M; Hatori N; Furuki T; Sakai H; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Yamamoto H; Machimura H; Chin K; Hishiki T; Takihata M; Aoyama K; Umezawa S; Minamisawa K; Aoyama T; Hamada Y; Suzuki Y; Hayashi M; Hatori Y; Sato K; Miyakawa M; Tamura K; Kanamori A
    J Diabetes Investig; 2021 Jan; 12(1):74-81. PubMed ID: 32506833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: A propensity-matched cohort study.
    Cheung JTK; Yang A; Wu H; Lau ESH; Shi M; Kong APS; Ma RCW; Luk AOY; Chan JCN; Chow E
    Diabetes Res Clin Pract; 2023 Jan; 195():110203. PubMed ID: 36493912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.